A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01363388 |
Recruitment Status :
Completed
First Posted : June 1, 2011
Results First Posted : July 27, 2020
Last Update Posted : July 27, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vasculitis | Drug: Placebo Drug: CCX168 | Phase 2 |
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with AAV on background cyclophosphamide or rituximab treatment.
The primary efficacy objective is to evaluate the efficacy of CCX168 based on the Birmingham Vasculitis Activity Score (BVAS) version 3.
The secondary objectives of this study include assessment of the feasibility of reducing or eliminating the use of corticosteroids in the treatment of subjects with ANCA-associated vasculitis without the need for rescue corticosteroid measures and the effect of CCX168 on several disease parameters.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 67 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment |
Study Start Date : | August 2011 |
Actual Primary Completion Date : | October 2015 |
Actual Study Completion Date : | January 2016 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo |
Drug: Placebo
BID for 84 days |
Experimental: CCX168
Active study medication
|
Drug: CCX168
BID for 84 days |
- Proportion of Subjects Achieving at Least 50% Reduction in Birmingham Vasculitis Activity Score [BVAS] by Week 12 and No Worsening in Any Body System [ Time Frame: 84 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Clinical diagnosis of granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis or renal limited vasculitis
- Male and postmenopausal or surgically sterile female subjects aged at least 18 years with new or relapsed AAV where treatment with cyclophosphamide or rituximab would be required
- Positive indirect immunofluorescence (IIF) test for P-ANCA or C-ANCA, or positive ELISA test for anti-proteinase-3 (PR3) or anti-myeloperoxidase (MPO) at screening
- Estimated glomerular filtration rate (eGFR) ≥ 20mL/min
- Have at least one "major" item, or at least 3 non-major items, or at least 2 renal items on the BVAS version 3
Key Exclusion Criteria:
- Severe disease as determined by rapidly progressive glomerulonephritis, alveolar hemorrhage, hemoptysis, rapid-onset mononeuritis multiplex or central nervous system involvement
- Any other multi-system autoimmune disease
- Medical history of coagulopathy or bleeding disorder
- Received cyclophosphamide within 12 weeks of screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1
- Received high-dose intravenous corticosteroids within 4 weeks of screening
- On an oral dose of a corticosteroid of more than 10mg prednisone-equivalent at the time of screening
- Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred; received anti-TNF treatment, abatacept, alemtuzumab, IVIg or plasma exchange within 12 weeks of screening

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01363388
Austria | |
Feldkirch, Austria | |
Innsbruck, Austria | |
Linz, Austria | |
Belgium | |
Brussels, Belgium | |
Edegem, Belgium | |
Gent, Belgium | |
Leuven, Belgium | |
Liege, Belgium | |
Roeselare, Belgium | |
Czechia | |
Prague, Czechia | |
France | |
Bordeaux, France | |
Boulogne sur Mer, France | |
Brest, France | |
Colmar, France | |
Grenoble, France | |
Nantes, France | |
Paris, France | |
Saint Jacques, France | |
Valenciennes, France | |
Germany | |
Berlin, Germany | |
Cologne, Germany | |
Dresden, Germany | |
Freiburg, Germany | |
Fulda, Germany | |
Heidelberg, Germany | |
Hungary | |
Budapest, Hungary | |
Netherlands | |
Groningen, Netherlands | |
Leiden, Netherlands | |
Rotterdam, Netherlands | |
Utrecht, Netherlands | |
Poland | |
Bialystok, Poland | |
Katowice, Poland | |
Szczecin, Poland | |
Wroclaw, Poland | |
Sweden | |
Linkoping, Sweden | |
Lund, Sweden | |
Malmo, Sweden | |
Stockholm, Sweden | |
United Kingdom | |
Berkshire, United Kingdom | |
Birmingham, United Kingdom | |
Cambridge, United Kingdom | |
London, United Kingdom | |
Manchester, United Kingdom | |
Oxford, United Kingdom |
Study Director: | Pirow Bekker, MD, PhD | ChemoCentryx Inc |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | ChemoCentryx |
ClinicalTrials.gov Identifier: | NCT01363388 |
Other Study ID Numbers: |
CL002_168 |
First Posted: | June 1, 2011 Key Record Dates |
Results First Posted: | July 27, 2020 |
Last Update Posted: | July 27, 2020 |
Last Verified: | July 2020 |
Vasculitis Vascular Diseases Cardiovascular Diseases |